1. Academic Validation
  2. Loss of OVOL2 in Triple-Negative Breast Cancer Promotes Fatty Acid Oxidation Fueling Stemness Characteristics

Loss of OVOL2 in Triple-Negative Breast Cancer Promotes Fatty Acid Oxidation Fueling Stemness Characteristics

  • Adv Sci (Weinh). 2024 Apr 16:e2308945. doi: 10.1002/advs.202308945.
Ruipeng Lu 1 Jingjing Hong 1 Tong Fu 1 Yu Zhu 1 Ruiqi Tong 1 Di Ai 1 Shuai Wang 1 Qingsong Huang 1 Ceshi Chen 2 3 Zhiming Zhang 4 Rui Zhang 5 Huiling Guo 1 Boan Li 1
Affiliations

Affiliations

  • 1 State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, 361104, China.
  • 2 Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361009, China.
  • 3 Xiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
  • 4 The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China.
  • 5 Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China.
Abstract

Triple-negative breast Cancer (TNBC), the most aggressive subtype of breast Cancer, has a poor prognosis and lacks effective treatment strategies. Here, the study discovered that TNBC shows a decreased expression of epithelial transcription factor ovo-like 2 (OVOL2). The loss of OVOL2 promotes fatty acid oxidation (FAO), providing additional energy and NADPH to sustain stemness characteristics, including sphere-forming capacity and tumor initiation. Mechanistically, OVOL2 not only suppressed STAT3 phosphorylation by directly inhibiting JAK transcription but also recruited histone deacetylase 1 (HDAC1) to STAT3, thereby reducing the transcriptional activation of downstream genes carnitine palmitoyltransferase1 (CPT1A and CPT1B). PyVT-Ovol2 knockout mice develop a higher number of primary breast tumors with accelerated growth and increased lung-metastases. Furthermore, treatment with FAO inhibitors effectively reduces stemness characteristics of tumor cells, breast tumor initiation, and metastasis, especially in OVOL2-deficient breast tumors. The findings suggest that targeting JAK/STAT3 pathway and FAO is a promising therapeutic strategy for OVOL2-deficient TNBC.

Keywords

FAO; JAK/STAT3; Ovol2; TNBC; stemness characteristics.

Figures
Products
Inhibitors & Agonists
Other Products